DNA Adducts in Cancer Chemotherapy
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02476 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yupeng Li. Hauptthemen laut MEDLINE: DNA Adducts, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 271 Literaturangaben. Gefördert von: University of Texas System, University of Texas at El Paso.
Themen: Onkologische Pflege
Abstract (Originalsprache)
DNA adducting drugs, including alkylating agents and platinum-containing drugs, are prominent in cancer chemotherapy. Their mechanisms of action involve direct interaction with DNA, resulting in the formation of DNA addition products known as DNA adducts. While these adducts are well-accepted to induce cancer cell death, understanding of their specific chemotypes and their role in drug therapy response remain limited. This perspective aims to address this gap by investigating the metabolic activation and chemical characterization of DNA adducts formed by the U.S. FDA-approved drugs. Moreover, clinical studies on DNA adducts as potential biomarkers for predicting patient responses to drug efficacy are examined. The overarching goal is to engage the interest of medicinal chemists and stimulate further research into the use of DNA adducts as biomarkers for guiding personalized cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Yupeng Li
Förderung
- University of Texas System
- University of Texas at El Paso
Zitieren
APA
Li, Y. (2024). DNA Adducts in Cancer Chemotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02476
Vancouver
Li Y. DNA Adducts in Cancer Chemotherapy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02476
BibTeX
@article{Li2024,
author = {Li, Yupeng},
title = {DNA Adducts in Cancer Chemotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02476}
}
EUVIMED